Aclaris shares halved after mid-stage skin disorder fail
A Pennsylvania biotech missed the mark on multiple fronts in a mid-stage trial — and investors are not happy.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
